SCHEMBL2946732

SCHEMBL2946732

CCc1sc(-c2ccc(C(=O)O)cc2)nc1C(=O)OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.78
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 1/20 0.51
LMNA P02545 1/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
KMT2A Q03164 1/20 0.51
RARB P10826 4/20 0.46
RARA P10276 2/20 0.46
RARG P13631 2/20 0.46
CSNK2A2 P19784 2/20 0.46
CSNK2A1 P68400 2/20 0.46
TRPM8 Q7Z2W7 1/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
HDAC6 Q9UBN7 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18003085 0.86 L3MBTL1 (0.78) L3MBTL1ALDH1A1KDM4EMEN1LMNA
SCHEMBL18003676 0.85 L3MBTL1 (0.76) L3MBTL1KDM4ELMNAMAPTKMT2A
SCHEMBL18003089 0.85 L3MBTL1 (0.76) L3MBTL1ALDH1A1KDM4EMEN1LMNA
SCHEMBL18003454 0.82 L3MBTL1 (0.70) L3MBTL1ALDH1A1KDM4EMEN1GAA
SCHEMBL18003704 0.80 L3MBTL1 (0.67) L3MBTL1ALDH1A1KDM4EMEN1MAPT
SCHEMBL18003897 0.79 L3MBTL1 (0.65) L3MBTL1ALDH1A1KDM4EMEN1LMNA
SCHEMBL18003371 0.77 L3MBTL1 (0.67) L3MBTL1ALDH1A1KDM4ELMNAGAA
SCHEMBL18003595 0.77 L3MBTL1 (0.67) L3MBTL1ALDH1A1KDM4EMEN1LMNA
SCHEMBL18003208 0.77 L3MBTL1 (0.62) L3MBTL1ALDH1A1KDM4EMEN1LMNA
SCHEMBL18003356 0.77 L3MBTL1 (0.62) L3MBTL1ALDH1A1KDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 L3MBTL1 189/4885ALDH1A1 2651/4885KDM4E 1911/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 L3MBTL1 107/4885ALDH1A1 2460/4885KDM4E 1563/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 L3MBTL1 189/4885ALDH1A1 2651/4885KDM4E 1911/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR L3MBTL1 138/4885ALDH1A1 3404/4885KDM4E 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.